Cohort builder
Which patient groups are most at risk?
Build your group
Base rule: RA diagnosis (2+ claims), RF or anti-CCP positive, age 18+, last 24 months
Region
Age band
Comorbidity
Prior therapy
In plain language:All new RA patients
40,000
Patients in group
100.0% of cohort
54
Median age
27.5%
Abandonment
Cohort 27.5%
19.7%
Brand X switch share
Groups at risk
Region and prior therapy segments with at least 50 new Brand X prescriptions, ranked by abandonment
Mid-South · Steroids only209 Rx
43.5%
North-East · Steroids only332 Rx
42.8%
Mid-South · Prior biologic297 Rx
41.8%
North-East · Methotrexate only1,142 Rx
40.3%
Mid-South · Methotrexate only798 Rx
40.1%
Mid-South · Methotrexate + other conventional416 Rx
39.9%
North-East · Methotrexate + other conventional643 Rx
37.3%
North-East · Prior biologic450 Rx
35.8%
Learn and improve.Every data refresh sharpens the next question and the next action.